Targeted Oncology Staff

In separate, virtual live events, Sarah Sammons, MD, and Ruth O’Regan, MD, discussed molecular profiling and therapeutic options for a patient with advanced breast cancer after multiple lines of therapy.

During a Case-Based Roundtable® event, Ariel F. Grajales-Cruz, MD, discussed data from the KarMMa-3 trial of idecabtagene vicleucel and real-world data on the CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants how they manage toxicity of transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Jack Khouri, MD, discussed data from the GRIFFIN, PERSEUS, and MASTER trials that investigated quadruplet therapy in patients with newly diagnosed multiple myeloma.

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, looks at options for a patients with hormone receptor–positive, HER2-negative breast cancer and an ESR1 mutation in the second article of a 2-part series.

During a Case-Based Roundtable® event, Stephanie A. Berg, DO, moderated a discussion on the impact of adverse events and dosing approaches on treatment of metastatic renal cell carcinoma.

During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses the adverse events, like capillary leak syndrome, that come with the use of tagraxofusp when treating patients with blastic plasmacytoid dendritic cell neoplasm in the second article of a 2-part series.

During a Case-Based Roundtable® event, Nikolai Podoltsev, MD, PhD, discussed appropriate JAK inhibitor therapy options for a 62-year-old patient with myelofibrosis who had potentially declining hemoglobin and platelet counts.

During a Case-Based Roundtable® event, Nakhle Saba, MD, discussed the role of Bruton tyrosine kinase inhibitors for patients with relapsed or refractory chronic lymphocytic leukemia, especially in patients with a poor health history.

During a Case-Based Roundtable® event, Julia Rotow, MD, continued a discussion on how biomarker testing for patients with non–small cell lung cancer impacts treatment decisions in the second article of a 2-part series.

In the case of a woman with metastatic non–small cell lung cancer, answer question of what you would do in terms of treatment and management, as well as questions about your practice.

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed long-term outcomes of the TIVO-3 trial in patients with metastatic clear cell renal cell carcinoma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed how the use of the isatuximab, carfilzomib, and dexamethasone triplet regimen led to deeper responses in patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants about quadruplet vs triplet regimens and the goals of deep responses in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

In an in-person Community Case Forum event in partnership with the North Carolina Oncology Association and South Carolina Oncology Society, Daniel Carrizosa, MD, MS, discussed the use of the immunotherapies durvalumab and atezolizumab in patients with small cell lung cancer.

During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed how the burgeoning use of chimeric antigen receptor T-cell therapy presents a paradigm shift in treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.

In separate live virtual events, James K. McCloskey II, MD, and Bart L. Scott, MD, polled participants on disease symptoms and bridging therapy options for a patient with primary myelofibrosis (PMF).

During a Case-Based Roundtable® event, Timothy J. Pluard, MD, discussed the use of sacituzumab govitecan advanced breast cancer as well as dosing considerations in the first article of a 2-part series.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.

During a Case-Based Roundtable® event, Sumanta K. Pal, MD, moderated a discussion on quality of life data and experiences with dose discontinuation of frontline combination therapy for patients with renal cell carcinoma.

During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.

During a Case-Based Roundtable® event, Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with diffuse large B-cell lymphoma whose disease relapsed eight months after completion of standard R-CHOP.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.

During a Case-Based Roundtable® event, Jubilee Brown, MD, discussed the efficacy and safety data from the KEYNOTE-775/Study 309 trial of lenvatinib plus pembrolizumab in patients with mismatch repair proficient advanced endometrial cancer.

During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.

During a Case-Based Roundtable® event, Michael B. Atkins, MD, discussed the choice of therapy for a 78-year-old patient with metastatic melanoma with participants.

During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Natalia Neparidze, MD, discussed the studies that led to accelerated approval of the bispecific T-cell engagers teclistamab and elranatamab in patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.